Chris you are on sound footing with your thoughtfu

Chris you are on sound footing with your thoughtful reply - as usual - and I agree - its a well written response. You Sir have gained my respect and my attention. However, I think we have had an obvious question of symantics with respect to exactly what type of "partnership" we think of in terms of LymPro.

The MSA with ICON is surely a partnership agreement for continued CLIA enabling lab testing and studies - specifically titled ‘Fit for Purpose Flow Cytometry Assay Validation’. Yes, this will enivitably lead to greater global distribution network for LymPro, including central labs in Europe, Singapore, India and China that will allow LymPro to enter these new markets seamlessly through an already established distribution framework. However, as stated in the PR:

Quote:

---

"this arrangement is not a classic partnership , as Amarantus is maintaining all intellectual property rights to current and future versions of LymPro at the current time. "

---

http://www.thechairmansblog.com/amarantus-bio...4AwCP.dpuf

I thought it was important to again note the difference in partnership verbiage and how this one interpretation and subsequent level of expectations have changed the overall thought process for some of us - including myself. Good, bad or indifferent, moving forward with ICON is the way in which the BOA and BOD has choosen to go, and I do not nor have I questioned the esteemed 'brain trust' that is leading the charge. How information is disseminated to the public is another subject altogether.

In essence I truly believe that Gerald is looking for an EXIT from LymPro, but an exit is directly tied to revenue recognition and herein lies the key to a Classic Partnership, or a series of...or a spin off...or an outright sale.

Have a great day folks............

All the Best, JP